-
1
-
-
56549125038
-
Pharmacogenetics of warfarin: Development of a dosing algorithm for brazilian patients
-
18754001 10.1038/clpt.2008.166 1:CAS:528:DC%2BD1cXhtlOjtrzO
-
Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G (2008) Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 84:722-728
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 722-728
-
-
Perini, J.A.1
Struchiner, C.J.2
Silva-Assuncao, E.3
Santana, I.S.4
Rangel, F.5
Ojopi, E.B.6
Dias-Neto, E.7
Suarez-Kurtz, G.8
-
2
-
-
49949098665
-
The critical path of warfarin dosing: Finding an optimal dosing strategy using pharmacogenetics
-
18714317 10.1038/clpt.2008.133 1:CAS:528:DC%2BD1cXhtVShtr%2FL
-
Lesko LJ (2008) The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 84:301-303
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 301-303
-
-
Lesko, L.J.1
-
3
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data
-
19228618 10.1056/NEJMoa0809329
-
Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764
-
(2009)
N Engl J Med
, vol.360
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
Eriksson, N.3
Gage, B.F.4
Kimmel, S.E.5
Lee, M.T.6
Limdi, N.A.7
Page, D.8
Roden, D.M.9
Wagner, M.J.10
Caldwell, M.D.11
Johnson, J.A.12
-
4
-
-
42549147841
-
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes
-
DOI 10.1038/sj.clpt.6100453, PII 6100453
-
Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, Lee TH, Kuo CT, Sun FM, Chang YJ, Kuan PL, Chen YF, Charng MJ, Ray CY, Wu JY, Chen YT (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84:83-89 (Pubitemid 351861488)
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.84
, Issue.1
, pp. 83-89
-
-
Wen, M.-S.1
Lee, M.T.M.2
Chen, J.-J.3
Chuang, H.-P.4
Lu, L.-S.5
Chen, C.-H.6
Lee, T.-H.7
Kuo, C.-T.8
Sun, F.-M.9
Chang, Y.-J.10
Kuan, P.-L.11
Chen, Y.-F.12
Charng, M.-J.13
Ray, C.-Y.14
Wu, J.-Y.15
Chen, Y.-T.16
-
5
-
-
66149103700
-
Study on binding of drug to serum protein
-
19336995 10.1248/yakushi.129.413 1:CAS:528:DC%2BD1MXotFWrtL0%3D
-
Otagiri M (2009) Study on binding of drug to serum protein. Yakugaku Zasshi 129:413-425
-
(2009)
Yakugaku Zasshi
, vol.129
, pp. 413-425
-
-
Otagiri, M.1
-
6
-
-
0031058095
-
Human orosomucoid polymorphism: Molecular basis of the three common ORM1 alleles, ORM1(*)F1,ORM1(*)F2, and ORM1(*)S
-
DOI 10.1007/s004390050378
-
Yuasa I, Umetsu K, Vogt U, Nakamura H, Nanba E, Tamaki N, Irizawa Y (1997) Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 99:393-398 (Pubitemid 27095804)
-
(1997)
Human Genetics
, vol.99
, Issue.3
, pp. 393-398
-
-
Yuasa, I.1
Umetsu, K.2
Vogt, U.3
Nakamura, H.4
Nanba, E.5
Tamaki, N.6
Irizawa, Y.7
-
7
-
-
0027358933
-
Genetic polymorphism of orosomucoid (ORM) in populations of the United Kingdom, Indian subcontinent, and Cambodia
-
Mastana SS, Jayasekara R, Fisher P, Sokol RJ, Papiha SS (1993) Genetic polymorphism of orosomucoid (ORM) in populations of the United Kingdom, Indian subcontinent, and Cambodia. Jpn J Hum Genet 38:289-296 (Pubitemid 23356028)
-
(1993)
Japanese Journal of Human Genetics
, vol.38
, Issue.3
, pp. 289-296
-
-
Mastana, S.S.1
Jayasekara, R.2
Fisher, P.3
Sokoi, R.J.4
Paphia, S.S.5
-
8
-
-
0032823184
-
Genetic polymorphisms of orosomucoid on the Han population in Nanjing of China
-
DOI 10.1016/S0009-8981(99)00157-6, PII S0009898199001576
-
Li JH, Xu JQ, Li Y, Zhuang YY, Gong JB (1999) Genetic polymorphisms of orosomucoid on the Han population in Nanjing of China. Clin Chim Acta 288:161-168 (Pubitemid 29472425)
-
(1999)
Clinica Chimica Acta
, vol.288
, Issue.1-2
, pp. 161-168
-
-
Li, J.-H.1
Xu, J.-Q.2
Li, Y.3
Zhuang, Y.-Y.4
Gong, J.-B.5
-
9
-
-
0036155217
-
Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine
-
DOI 10.1016/S0009-8981(01)00763-X, PII S000989810100763X
-
Li JH, Xu JQ, Cao XM, Ni L, Li Y, Zhuang YY, Gong JB (2002) Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin Chim Acta 317:85-92 (Pubitemid 34114022)
-
(2002)
Clinica Chimica Acta
, vol.317
, Issue.1-2
, pp. 85-92
-
-
Li, J.-H.1
Xu, J.-Q.2
Cao, X.-M.3
Ni, L.4
Li, Y.5
Zhuang, Y.-Y.6
Gong, J.-B.7
-
10
-
-
0021982083
-
1-acid glycoprotein
-
DOI 10.1007/BF00547045
-
Tinguely D, Baumann P, Conti M, Jonzier-Perey M, Schopf J (1985) Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein. Eur J Clin Pharmacol 27:661-666 (Pubitemid 15167087)
-
(1985)
European Journal of Clinical Pharmacology
, vol.27
, Issue.6
, pp. 661-666
-
-
Tinguely, D.1
Baumann, P.2
Conti, M.3
-
11
-
-
42149139502
-
Influence of ORM1 polymorphism on serum concentration of free nortriptyline
-
17944232 1:CAS:528:DC%2BD1cXht1Sjs7k%3D
-
Zhang C, Tu ZL, Wang QB, Cheng XL, Zhang PH (2007) Influence of ORM1 polymorphism on serum concentration of free nortriptyline. Yao Xue Xue Bao 42:843-848
-
(2007)
Yao Xue Xue Bao
, vol.42
, pp. 843-848
-
-
Zhang, C.1
Tu, Z.L.2
Wang, Q.B.3
Cheng, X.L.4
Zhang, P.H.5
-
12
-
-
33749240384
-
1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation
-
DOI 10.1016/j.clpt.2006.06.006, PII S0009923606002517
-
Colombo S, Buclin T, Decosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, Eap CB (2006) Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 80:307-318 (Pubitemid 44479747)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.80
, Issue.4
, pp. 307-318
-
-
Colombo, S.1
Buclin, T.2
Decosterd, L.A.3
Telenti, A.4
Furrer, H.5
Lee, B.L.6
Biollaz, J.7
Eap, C.B.8
-
13
-
-
0020419857
-
1-acid glycoprotein
-
DOI 10.1016/0006-2952(82)90597-4
-
Urien S, Albengres E, Zini R, Tillement JP (1982) Evidence for binding of certain acidic drugs to alpha1-acid glycoprotein. Biochem Pharmacol 31:3687-3689 (Pubitemid 13244140)
-
(1982)
Biochemical Pharmacology
, vol.31
, Issue.22
, pp. 3687-3689
-
-
Urein, S.1
Albengres, E.2
Zini, R.3
Tillement, J.P.4
-
14
-
-
0345374664
-
1-acid glycoprotein variants
-
DOI 10.1046/j.1365-2125.2003.01909.x
-
Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K (2003) Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol 56:664-669 (Pubitemid 37491719)
-
(2003)
British Journal of Clinical Pharmacology
, vol.56
, Issue.6
, pp. 664-669
-
-
Nakagawa, T.1
Kishino, S.2
Itoh, S.3
Sugawara, M.4
Miyazaki, K.5
-
15
-
-
73649117856
-
Genetic determinants of warfarin dosing in the Han-Chinese population
-
19958090 10.2217/pgs.09.106 1:CAS:528:DC%2BD1MXhsFSqtbzF
-
Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT (2009) Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10:1905-1913
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1905-1913
-
-
Lee, M.T.1
Chen, C.H.2
Chou, C.H.3
Lu, L.S.4
Chuang, H.P.5
Chen, Y.T.6
Saleem, A.N.7
Wen, M.S.8
Chen, J.J.9
Wu, J.Y.10
Chen, Y.T.11
-
16
-
-
50249160170
-
Genetic factors contribute to patient-specific warfarin dose for Han Chinese
-
18680736 10.1016/j.cca.2008.07.005 1:CAS:528:DC%2BD1cXhtVKmsr3K
-
Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M, Tai S (2008) Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 396:76-79
-
(2008)
Clin Chim Acta
, vol.396
, pp. 76-79
-
-
Wang, T.L.1
Li, H.L.2
Tjong, W.Y.3
Chen, Q.S.4
Wu, G.S.5
Zhu, H.T.6
Hou, Z.S.7
Xu, S.8
Ma, S.J.9
Wu, M.10
Tai, S.11
-
17
-
-
66649135003
-
-
Warfarin pharmacogenetics 2475
-
Shil AB, Strohm MP (2009) Warfarin pharmacogenetics. N Engl J Med 360:2474-75, 2475
-
(2009)
N Engl J Med
, vol.360
, pp. 2474-2475
-
-
Shil, A.B.1
Strohm, M.P.2
-
18
-
-
66649135003
-
Warfarin pharmacogenetics
-
19494226 10.1056/NEJMc090579 1:CAS:528:DC%2BD1MXntVKqs7k%3D
-
Garcia DA, Hylek E (2009) Warfarin pharmacogenetics. N Engl J Med 360:2474-2475
-
(2009)
N Engl J Med
, vol.360
, pp. 2474-2475
-
-
Garcia, D.A.1
Hylek, E.2
-
19
-
-
63449117825
-
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose
-
19300499 10.1371/journal.pgen.1000433
-
Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e1000433
-
(2009)
PLoS Genet
, vol.5
, Issue.3
, pp. 1000433
-
-
Takeuchi, F.1
McGinnis, R.2
Bourgeois, S.3
Barnes, C.4
Eriksson, N.5
Soranzo, N.6
Whittaker, P.7
Ranganath, V.8
Kumanduri, V.9
McLaren, W.10
Holm, L.11
Lindh, J.12
Rane, A.13
Wadelius, M.14
Deloukas, P.15
-
20
-
-
66849132349
-
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant
-
19297519 10.1124/mol.109.054833 1:CAS:528:DC%2BD1MXmvVWqsb8%3D
-
McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE (2009) CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75(6):1337-1346
-
(2009)
Mol Pharmacol
, vol.75
, Issue.6
, pp. 1337-1346
-
-
McDonald, M.G.1
Rieder, M.J.2
Nakano, M.3
Hsia, C.K.4
Rettie, A.E.5
-
21
-
-
42149188553
-
CYP4F2 genetic variant alters required warfarin dose
-
18250228 10.1182/blood-2007-11-122010 1:CAS:528:DC%2BD1cXkvFeis7g%3D
-
Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8):4106-4112
-
(2008)
Blood
, vol.111
, Issue.8
, pp. 4106-4112
-
-
Caldwell, M.D.1
Awad, T.2
Johnson, J.A.3
Gage, B.F.4
Falkowski, M.5
Gardina, P.6
Hubbard, J.7
Turpaz, Y.8
Langaee, T.Y.9
Eby, C.10
King, C.R.11
Brower, A.12
Schmelzer, J.R.13
Glurich, I.14
Vidaillet, H.J.15
Yale, S.H.16
Qi Zhang, K.17
Berg, R.L.18
Burmester, J.K.19
-
22
-
-
65549085682
-
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
-
19207028 10.2217/14622416.10.2.261 1:CAS:528:DC%2BD1MXhslSgu7o%3D
-
Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2):261-266
-
(2009)
Pharmacogenomics
, vol.10
, Issue.2
, pp. 261-266
-
-
Borgiani, P.1
Ciccacci, C.2
Forte, V.3
Sirianni, E.4
Novelli, L.5
Bramanti, P.6
Novelli, G.7
-
23
-
-
72849127064
-
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
-
19794411 10.1038/clpt.2009.178 1:CAS:528:DC%2BD1MXhsFOms7bP
-
Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahé I, Legendre C, Taillandier-Hériche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 87(1):57-64
-
(2010)
Clin Pharmacol Ther
, vol.87
, Issue.1
, pp. 57-64
-
-
Pautas, E.1
Moreau, C.2
Gouin-Thibault, I.3
Golmard, J.L.4
Mahé, I.5
Legendre, C.6
Taillandier-Hériche, E.7
Durand-Gasselin, B.8
Houllier, A.M.9
Verrier, P.10
Beaune, P.11
Loriot, M.A.12
Siguret, V.13
-
24
-
-
84859565615
-
-
Observational Cohort Study Clin Ther
-
Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y (2012) Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label. Observational Cohort Study. Clin Ther 34(4):811-23
-
(2012)
Effects of CYP4F2 Polymorphism on Response to Warfarin during Induction Phase: A Prospective, Open-label
-
-
Bejarano-Achache, I.1
Levy, L.2
Mlynarsky, L.3
Bialer, M.4
Muszkat, M.5
Caraco, Y.6
-
25
-
-
70349574149
-
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
-
19741565 10.1097/FPC.0b013e3283311347 1:CAS:528:DC%2BD1MXhtFGlsLbO
-
Zhang JE, Jorgensen AL, Alfirevic A, Williamson PR, Toh CH, Park BK, Pirmohamed M (2009) Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 19(10):781-789
-
(2009)
Pharmacogenet Genomics
, vol.19
, Issue.10
, pp. 781-789
-
-
Zhang, J.E.1
Jorgensen, A.L.2
Alfirevic, A.3
Williamson, P.R.4
Toh, C.H.5
Park, B.K.6
Pirmohamed, M.7
-
26
-
-
77949876162
-
Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort
-
20182420 10.1038/clpt.2009.307 1:CAS:528:DC%2BC3cXjs1ajsbc%3D
-
Perini JA, Struchiner CJ, Silva-Assunção E, Suarez-Kurtz G (2010) Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 87(4):417-420
-
(2010)
Clin Pharmacol Ther
, vol.87
, Issue.4
, pp. 417-420
-
-
Perini, J.A.1
Struchiner, C.J.2
Silva-Assunção, E.3
Suarez-Kurtz, G.4
-
27
-
-
84861150804
-
Influence of CYP4F2 genotype on warfarin dose requirement - A systematic review and meta-analysis
-
22192158 10.1016/j.thromres.2011.11.043 1:CAS:528:DC%2BC38XotVeks7k%3D
-
Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y (2012) Influence of CYP4F2 genotype on warfarin dose requirement - a systematic review and meta-analysis. Thromb Res 130(1):38-44
-
(2012)
Thromb Res
, vol.130
, Issue.1
, pp. 38-44
-
-
Liang, R.1
Wang, C.2
Zhao, H.3
Huang, J.4
Hu, D.5
Sun, Y.6
-
28
-
-
33947227273
-
Association of warfarin dose with genes involved in its action and metabolism
-
DOI 10.1007/s00439-006-0260-8
-
Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23-34 (Pubitemid 46421137)
-
(2007)
Human Genetics
, vol.121
, Issue.1
, pp. 23-34
-
-
Wadelius, M.1
Chen, L.Y.2
Eriksson, N.3
Bumpstead, S.4
Ghori, J.5
Wadelius, C.6
Bentley, D.7
McGinnis, R.8
Deloukas, P.9
-
29
-
-
34547112822
-
Building individualized medicine: Prevention of adverse reactions to warfarin therapy
-
DOI 10.1124/jpet.106.117952
-
Krynetskiy E, McDonnell P (2007) Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 322:427-434 (Pubitemid 47105770)
-
(2007)
Journal of Pharmacology and Experimental Therapeutics
, vol.322
, Issue.2
, pp. 427-434
-
-
Krynetskiy, E.1
McDonnell, P.2
-
30
-
-
34147162376
-
Pharmacogenetics of warfarin: Current status and future challenges
-
DOI 10.1038/sj.tpj.6500417, PII 6500417
-
Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99-111 (Pubitemid 46567142)
-
(2007)
Pharmacogenomics Journal
, vol.7
, Issue.2
, pp. 99-111
-
-
Wadelius, M.1
Pirmohamed, M.2
-
31
-
-
51649110496
-
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
-
18535201 10.1182/blood-2008-01-134247 1:CAS:528:DC%2BD1cXpvVOksLs%3D
-
Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027
-
(2008)
Blood
, vol.112
, pp. 1022-1027
-
-
Cooper, G.M.1
Johnson, J.A.2
Langaee, T.Y.3
Feng, H.4
Stanaway, I.B.5
Schwarz, U.I.6
Ritchie, M.D.7
Stein, C.M.8
Roden, D.M.9
Smith, J.D.10
Veenstra, D.L.11
Rettie, A.E.12
Rieder, M.J.13
-
32
-
-
59649117935
-
The largest prospective warfarin-treated cohort supports genetic forecasting
-
18574025 10.1182/blood-2008-04-149070 1:CAS:528:DC%2BD1MXhtlGhsbc%3D
-
Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792
-
(2009)
Blood
, vol.113
, Issue.4
, pp. 784-792
-
-
Wadelius, M.1
Chen, L.Y.2
Lindh, J.D.3
Eriksson, N.4
Ghori, M.J.5
Bumpstead, S.6
Holm, L.7
McGinnis, R.8
Rane, A.9
Deloukas, P.10
-
33
-
-
0015892271
-
Kinetics of warfarin absorption in man
-
4584153 1:CAS:528:DyaE2cXktVSjtr0%3D
-
Breckenridge A, Orme M (1973) Kinetics of warfarin absorption in man. Clin Pharmacol Ther 14:955-961
-
(1973)
Clin Pharmacol Ther
, vol.14
, pp. 955-961
-
-
Breckenridge, A.1
Orme, M.2
-
34
-
-
0006870774
-
-
Warfarin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied Therapeutics, Inc, Vancouver 31-46
-
Porter RS, Sawyer WT (1992) Warfarin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics. Applied Therapeutics, Inc, Vancouver, pp 31-1 to 31-46
-
(1992)
Applied Pharmacokinetics
, pp. 31-41
-
-
Porter, R.S.1
Sawyer, W.T.2
-
35
-
-
0015212913
-
Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs
-
10.1111/j.1749-6632.1971.tb46901.x
-
Seller EM, Koch-Weser J (1971) Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci 170:213-225
-
(1971)
Ann N y Acad Sci
, vol.170
, pp. 213-225
-
-
Seller, E.M.1
Koch-Weser, J.2
-
36
-
-
45749156422
-
Evaluation of a potential tigecycline-warfarin drug interaction
-
DOI 10.1592/phco.28.7.895
-
Zimmerman JJ, Raible DG, Harper DM, Matschke K, Speth JL (2008) Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy 28(7):895-905 (Pubitemid 351875168)
-
(2008)
Pharmacotherapy
, vol.28
, Issue.7
, pp. 895-905
-
-
Zimmerman, J.J.1
Raible, D.G.2
Harper, D.M.3
Matschke, K.4
Speth, J.L.5
Korth-Bradley, J.M.6
-
37
-
-
70349649709
-
A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein
-
19198000 10.1002/jps.21697 1:CAS:528:DC%2BD1MXhtF2qtLjF
-
Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D, Watanabe H, Suenaga A, Maruyama T, Otagiri M (2009) A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J Pharm Sci 98:4316-4326
-
(2009)
J Pharm Sci
, vol.98
, pp. 4316-4326
-
-
Nishi, K.1
Ueno, M.2
Murakami, Y.3
Fukunaga, N.4
Akuta, T.5
Kadowaki, D.6
Watanabe, H.7
Suenaga, A.8
Maruyama, T.9
Otagiri, M.10
-
38
-
-
0029051687
-
Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects
-
7657852 10.1002/j.1552-4604.1995.tb04096.x 1:CAS:528:DyaK2MXmt1Kktb4%3D
-
Kishino S, Nomura A, Di ZS, Sugawara M, Iseki K, Kakinoki S, Kitabatake A, Miyazaki K (1995) Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol 35:510-514
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 510-514
-
-
Kishino, S.1
Nomura, A.2
Di, Z.S.3
Sugawara, M.4
Iseki, K.5
Kakinoki, S.6
Kitabatake, A.7
Miyazaki, K.8
-
39
-
-
0023685931
-
Binding of amitriptyline to alpha 1-acid glycoprotein and its variants
-
2907555 10.1111/j.2042-7158.1988.tb05169.x 1:CAS:528:DyaL1MXitFM%3D
-
Eap CB, Cuendet C, Baumann P (1988) Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J Pharm Pharmacol 40:767-770
-
(1988)
J Pharm Pharmacol
, vol.40
, pp. 767-770
-
-
Eap, C.B.1
Cuendet, C.2
Baumann, P.3
-
40
-
-
84892677328
-
Serum A1-Acid glycoprotein concentrations in 213 healthy male subjects and relative analysis with age
-
Li J, Li Y, Gong J, Zhuang K, Yiyi K, Xu J-Q (2009) Serum A1-Acid glycoprotein concentrations in 213 healthy male subjects and relative analysis with age. Acta Universitatis Medicinalis Nanjing 20(5):336-338
-
(2009)
Acta Universitatis Medicinalis Nanjing
, vol.20
, Issue.5
, pp. 336-338
-
-
Li, J.1
Li, Y.2
Gong, J.3
Zhuang, K.4
Yiyi, K.5
Xu, J.-Q.6
-
41
-
-
80052639544
-
Valproic acid and warfarin: An underrecognized drug interaction
-
21512888 10.1007/s12028-011-9544-5 1:CAS:528:DC%2BC3MXoslWitL0%3D
-
Yoon HW, Giraldo EA, Wijdicks EF (2011) Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care 15(1):182-185
-
(2011)
Neurocrit Care
, vol.15
, Issue.1
, pp. 182-185
-
-
Yoon, H.W.1
Giraldo, E.A.2
Wijdicks, E.F.3
-
42
-
-
0028959511
-
Hypothesized interaction between valproic acid and warfarin
-
7782487 10.1097/00004714-199504000-00010 1:STN:280:DyaK2MzgtFOgtw%3D%3D
-
Guthrie SK, Stoysich AM, Bader G, Hilleman DE (1995) Hypothesized interaction between valproic acid and warfarin. J Clin Psychopharmacol 15(2):138-139
-
(1995)
J Clin Psychopharmacol
, vol.15
, Issue.2
, pp. 138-139
-
-
Guthrie, S.K.1
Stoysich, A.M.2
Bader, G.3
Hilleman, D.E.4
-
44
-
-
0032492964
-
Influence of indinavir and ritonavir on warfarin anticoagulant activity [7]
-
Gatti G, Alessandrini A, Camera M, Di Biagio A, Bassetti M, Rizzo F (1998) Influence of indinavir and ritonavir on warfarin anticoagulant activity. Aids 12:825-826 (Pubitemid 28190712)
-
(1998)
AIDS
, vol.12
, Issue.7
, pp. 825-826
-
-
Gatti, G.1
Alessandrini, A.2
Camera, M.3
Di Biagio, A.4
Bassetti, M.5
Rizzo, F.6
-
45
-
-
0032425376
-
Potential interaction involving warfarin and ritonavir
-
DOI 10.1345/aph.17456
-
Knoell KR, Young TM, Cousins ES (1998) Potential interaction involving warfarin and ritonavir. Ann Pharmacother 32:1299-1302 (Pubitemid 29013352)
-
(1998)
Annals of Pharmacotherapy
, vol.32
, Issue.12
, pp. 1299-1302
-
-
Knoell, K.R.1
|